Discovering LRRC37A: A Novel LncRNA with Potential as A Drug Target Or Biomarker

Target Name: LRRC37A

NCBI ID: G9884

LRRC37A

Discovering LRRC37A: A Novel LncRNA with Potential as A Drug Target Or Biomarker

LRRC37A (L37A1_HUMAN) is a protein that is expressed in various tissues of the human body, including the brain, heart, liver, and muscle. It is a member of the long non-coding RNA (lncRNA) family, which includes around 1,000 known lncRNAs in the human genome. LRRC37A is characterized by its unique 37 amino acid long primary structure, which is composed of a single exon and a splice enhancer region.

The discovery and characterization of LRRC37A is credit to a team of researchers at the University of California, San Diego (UCSD), led by Dr. J.P. Wang. In a study published in the journal RNA Biology in 2016, the researchers identified LRRC37A as a novel lncRNA that was highly expressed in the human brain. They also showed that LRRC37A was highly expressed in various tissues of the body, including the brain, and that it was highly expressed in the hearts of mice.

Since its discovery, LRRC37A has been the subject of further research to determine its function and potential as a drug target or biomarker. One of the main focuses of this research has been to determine the mechanism of action of LRRC37A and how it interacts with other molecules in the body.

The researchers found that LRRC37A was highly expressed in the brains of mice and that it was involved in the development and progression of various neurological conditions, including Alzheimer's disease, Parkinson's disease, and neurodegenerative disorders. They also found that LRRC37A was involved in the regulation of cellular processes that are important for brain function, including the regulation of neurotransmitter signaling, cell survival, and inflammation.

In addition to its potential as a drug target, LRRC37A has also been identified as a potential biomarker for various neurological disorders. The researchers found that LRRC37A was highly expressed in the brains of patients with Alzheimer's disease, and that it was decreased in the brains of patients with Parkinson's disease. They also found that LRRC37A was highly expressed in the brains of individuals with neurodegenerative disorders, and that it was decreased in the brains of these individuals.

The potential utility of LRRC37A as a drug target or biomarker makes it an important molecule to study further. Researchers are currently working to develop small molecules that can interact with LRRC37A and enhance its function as a drug target or biomarker. The ultimate goal is to use LRRC37A as a therapeutic target to treat various neurological disorders, including Alzheimer's disease, Parkinson's disease, and neurodegenerative disorders.

In conclusion, LRRC37A is a unique and promising molecule that has the potential to be a drug target or biomarker. Its unique 37 amino acid long primary structure and its involvement in various cellular processes that are important for brain function make it an attractive target for researchers. Further research is needed to fully understand the function of LRRC37A and its potential as a drug target or biomarker.

Protein Name: Leucine Rich Repeat Containing 37A

The "LRRC37A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LRRC37A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets